Mercury Therapeutics was founded in 2001 to discover novel treatments for unmet medical needs by employing its proprietary proteomic-based technology to identify novel drug targets acting in signal transduction pathways critical to the control of energy metabolism, cell proliferation and inflammation. Our company's leadership consists of scientists and entrepreneurs with an outstanding track record of accomplishment.
Please use the links above to learn more about our team.